The cure for cancer has been one of the highest priorities of the medical world for decades, with scientists in both private and public fields trying their best to finally rid the world of the deadly disease. One group is closing in on a cure after publishing a paper indicating that they were able to reverse the conditions of terminally ill patients.
It’s well-known within the cancer community that the best way to head off cancer with current treatments is early diagnosis and an aggressive few rounds of chemotherapy, among other treatments. Once a patient reaches stage 4, their chances of survival diminish considerably. The US-based pharmaceutical company Kite Pharma is working on changing that and is making considerable headway.
The work that the company’s researchers were doing involve gene therapy and the trials yielded results that included terminally-ill patients going into remission after they were treated to just one round of trials. The trial itself lasted six months, with numerous subjects injected with modified T-cells.
For those who don’t know, T-cells are basically immune cells that are meant to destroy harmful invaders in the body. The genius of cancer cells is their ability to evade T-cells, which allows them to spread all over the body and multiply.
By genetically engineering these immune cells in order to make them more effective patrollers, they become better equipped to identify and eliminate cancer cells, Futurism reports. As a result, even patients who are at an advanced stage of the disease have a chance of cleansing their body of the illness.
As for the patients involved in the trials, they were divided based on which of the three types of non-Hodgkin lymphoma they had. Due to how advanced the stage of the cancer was in their bodies, most of the subjects were only given a few months to live. After the trials, many were given a second chance at life.


Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations
NASA's Artemis II Mission: First Crewed Lunar Journey Since Apollo
3 clinical-grade skincare creams you really shouldn’t buy online
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise
Blue Origin New Glenn Explosion Could Delay Launch Operations Until 2028
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak 



